COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Not yet submitted
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Studying the efficacy of using lidocaine and dexmedetomidine as an alternative to propofol to provide sedation for patients undergoing colonoscopy.
Scientific title
Testing the efficacy of Lidocaine and dexmedetomidine as an alternative to propofol for sedation in colonoscopy according to the patient satisfaction.
Secondary ID [1] 299442 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Sedation for colonoscopy 314640 0
Condition category
Condition code
Anaesthesiology 312981 312981 0 0
Oral and Gastrointestinal 313731 313731 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Study type
Description of intervention(s) / exposure
Patients scheduled for colonoscopy will be devided into two groups to receive either sedation by propofol infusion or by combined dexmedetomidine and lidocaine.
(A) propofol infusion at dose 25-75 ug/kg/min, Lidocaine infusion 1-2 mg/kg/hour and Dexmedetomidine infusion 0.2-0.5 ug/kg/min, all the infusions will start just before the beginning of the procedure.
(B) Drugs will be administered all-through the duration of the procedure
(C) Drugs will be administered by intravenous infusion
(D) The primary anesthesiologist ( the anesthesiologist who planned the methodology ) will be responsible for administration.
(E) The group who will receive lidocaine and Dexmedetomidine will be the intervention group
Intervention code [1] 315711 0
Treatment: Drugs
Comparator / control treatment
The control group will include patients who will receive propofol intravenous infusion for sedation for colonoscopy
Control group

Primary outcome [1] 321572 0
patient satisfaction by the procedure and sedation.
It will be assessed by a scale from 0 to 10 where 0 means not at all satisfied and 10 means maximally satisfied.
patient will be asked to give the scale score once he/she is fully awake.
Patient satisfaction is a composite primary outcome
Timepoint [1] 321572 0
immediately after recovery
Secondary outcome [1] 375405 0
Heart rate
monitored by ECG monitors
Timepoint [1] 375405 0
during the procedure
Secondary outcome [2] 375406 0
Apnic attacks .
assessed by clinical observation and monitoring.
apnic attacks means ( number of times where the patient stops breathing
Timepoint [2] 375406 0
during the procedure
Secondary outcome [3] 375407 0
Pain score , assessed by the numerical pain score
Timepoint [3] 375407 0
Immediately after recovery
Secondary outcome [4] 375408 0
time to discharge to home which will be known from the doctor order for discharge and the data will be collected from the medical records.
Timepoint [4] 375408 0
time of discharge
Secondary outcome [5] 377490 0
Blood pressure
continuously monitored by non-invasive bench-top sphygmomanometer
Timepoint [5] 377490 0
throughout the procedure
Secondary outcome [6] 377491 0
oxygen saturation by the pulse-oximetry
Timepoint [6] 377491 0
throughout the procedure

Key inclusion criteria
All adult ASA I and II patients admitted for elective colonoscopy
Minimum age
19 Years
Maximum age
70 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Patients with bradycardia (heart rate < 55/min).
Patients with known allergy to. lidocaine or dexemedotimidine

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
central randomization by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Who is / are masked / blinded?

Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 21898 0
United Arab Emirates
State/province [1] 21898 0

Funding & Sponsors
Funding source category [1] 303991 0
Name [1] 303991 0
NMC royal Hospital
Address [1] 303991 0
NMC Royal Hospital
Dubai Investment park
P.O Box: 7832- Dubai
United Arab Of emirates
Country [1] 303991 0
United Arab Emirates
Primary sponsor type
NMC Royal Hospital
Dubai Investment park
P.O Box: 7832
United Arab Emirates
Secondary sponsor category [1] 304165 0
Name [1] 304165 0
Address [1] 304165 0
Country [1] 304165 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 304449 0
NMC Hospital
Ethics committee address [1] 304449 0
Dubai Investment park
P.O Box: 7832
Ethics committee country [1] 304449 0
United Arab Emirates
Date submitted for ethics approval [1] 304449 0
Approval date [1] 304449 0
Ethics approval number [1] 304449 0

Brief summary
Colonoscopy is one of the most common day case procedures allover the world. Propofol has been the gold standard drug used for sedation and anesthesia for such cases.
In our trial we will examine the efficacy of using dexmedetomidine and lidocaine infusion as an alternative to propofol infusion in such cases
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 96982 0
Dr Tamer Hamed Ibrahim
Address 96982 0
NMC Royal Hospital
Dubai Investment Park
P.O Box: 7832
Country 96982 0
United Arab Emirates
Phone 96982 0
Fax 96982 0
Email 96982 0
Contact person for public queries
Name 96983 0
Dr Tamer Hamed Ibrahim
Address 96983 0
NMC Royal Hospital
Dubai Investment Park
PO Box: 7832
Country 96983 0
United Arab Emirates
Phone 96983 0
Fax 96983 0
Email 96983 0
Contact person for scientific queries
Name 96984 0
Dr Tamer Hamed Ibrahim
Address 96984 0
NMC Royal Hospital
Dubai Investment Park
P.O Box: 7832
Country 96984 0
United Arab Emirates
Phone 96984 0
Fax 96984 0
Email 96984 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
What data in particular will be shared?
patient data, primary and secondary outcome results
When will data be available (start and end dates)?
data will be available from 30 March 2020 till December 2020
Available to whom?
after publication results will be available to every body.
patient data will not be shared
Available for what types of analyses?
How or where can data be obtained?
by the primary author (
What supporting documents are/will be available?
Study protocol
Statistical analysis plan
How or where can supporting documents be obtained?
Type [1] 5252 0
Study protocol
Citation [1] 5252 0
Link [1] 5252 0
Email [1] 5252 0
Other [1] 5252 0
Attachment [1] 5252 0
Type [2] 5253 0
Statistical analysis plan
Citation [2] 5253 0
Link [2] 5253 0
Email [2] 5253 0
Other [2] 5253 0
Attachment [2] 5253 0
Summary results
No Results